13/01/2022

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents

The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States has offered an opportunity to assess the real-world effectiveness of the BNT162b2 messenger RNA vaccine in adolescents between 12 and 18 years of age.

Matéria original

Anterior

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Próxima

Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2